Understanding The Extreme Burden
Systemic lupus erythematosus (SLE) disrupts the lives of patients worldwide. The malady symptomatically displays as a hyperactive immune system with variance including extreme fatigue, pain, damage to the kidneys and other organs, and manifestations on the skin, to name a few. Since traditional methods of treating the illness via immunosuppression end up failing a patient, further research is warranted. There is a focus on the application of biological therapies as a way to treat this illness. One of the advanced methods of biological therapy is the use of umbilical cord-derived mesenchymal stem cells (UC-MSCs) therapy at a recognized stem cell clinic, which offers the therapy to alleviate the burdensome symptoms. Regenerative therapy is of priority to patients wishing to improve the years of their life without deterioration of their abilities. Patients suffering from SLE need more than solutions that only address the symptoms of the illness.
Understanding The Complex Biological Mechanisms
Immunoregulation on a complex and deep level is what this stem cell clinic therapy is able to offer the lupus patient. The therapy utilizing UC-MSCs has the ability to restore and maintain homeostasis within tissue through the therapy’s paracrine effects. This is achieved through the secretion of the cytokine interleukin 10, along with transforming growth factor β and PGE2, all of which create an anti-inflammatory environment. This therapy has the ability to control the overactive adaptive immune system, and more specifically, has the ability to create and maintain an immune system which is tolerant and regulated. This therapy has the ability to reinstate control and decrease the production of pathogenic B cells and the autoantibodies they produce. Another critical pathway for lupus treated by UC-MSCs at a stem cell clinic is dendritic cell maturation inhibition. Given that dendritic cells are professional antigen presenters, the inflammatory cascade is interrupted. As this happens, tissue repair is aided by the sustained release of specialized trophic factors.
Historically, physicians managing difficult cases of lupus relied on the arsenal of corticosteroids and other immunosuppressants. These medications manage the acute inflammation that arises during crisis. There are measurable side effects that are of great concern to both clinician and patient. These medications cause the rapid development of osteoporosis, the emergence of atypical viral infections, and slow the patient’s metabolism and cardiovascular health. There are also documented cases of patients not responding to aggressive therapy. These patients are subjected to an array of other medications while their disease continues to progress unmanageably. The aim of the medications is to control the surface manifestations of the disease. With the heavy medication burden, there is a pressing demand for a treatment utilizing UC-MSCs from a stem cell clinic that safely drains the systemic burden rather than suppressing disease progress.
UC-MSCs for lupus at a stem cell clinic
In this context, the addition of UC-MSCs for lupus at a stem cell clinic is a new treatment paradigm. They are not a pharmaceutical product that suppresses disease. Unlike the pharmaceutical alternative, UC-MSCs intervene on dysregulated immune pathways while allowing for the balance of immune inhibition. Unlike other cellular products, UC-MSCs are not immunogenic. Once UC-MSCs therapy is administered at a stem cell clinic for lupus, the stem cells move to the areas in the body where microenvironments are inflamed. The ability to target where the stem cells move means the body’s regulatory signals can be delivered to the precise locations. The stem cells interact with the autoimmune cells and induce the cells to self-destruct. The stem cells change the body’s immune system and lead to long periods of remission.
Figure 1: Understanding the complex biological mechanisms of UC-MSCs for lupus
Analyzing Local Developments in Thailand
Southeast Asia is poised to be the leader in the world for regenerative medicine in the near future and is the first region in the world to offer the advanced UC-MSCs protocol for treatment of severe lupus, particularly in Thailand. Thailand has world class medical facilities and has research facilities with international accreditations. Researchers in Thailand have been actively involved in cutting edge regenerative medicine research and are involved in international collaborations of research. There is a strong commitment of the Thai government to facilitate the use of new medical technologies. There is also a total commitment to research on the use of new medical technologies and a strong commitment to facilitate the use of new medical technologies. Thailand also offers excellent value for the use of cutting-edge medical technologies and this has led to an influx of international patients. A leading stem cell clinic in Thailand uses multidisciplinary approaches to therapy including the use and the development of advanced therapeutic cellular processing and the use of integrated patient monitoring and support systems.
Bringing Together the Transformative Power of Cellular Therapy
New approaches to medicine including the use of advanced cellular technologies are the only feasible means for the treatment of complex autoimmune diseases including systemic lupus. The use of UC-MSCs is an example of this type of innovative approach to modern clinical immunology utilized at a stem cell clinic. These UC-MSCs have the potential to modify the course of lupus in the long-term because they can correct immune responses that are fundamentally problematic. These cells have the ability to create long-term, full-body tolerance and do not have the debilitating side effects that other therapies have. These cells can change the outlook for patients around the world. As international medical research continues to develop, these expensive and complex therapies will be available in more specialized stem cell clinic facilities. These therapies give medical practitioners hope that these patients, who have chronically debilitating and severe autoimmune conditions, will have some relief.